Earnings Call · Q2 FY2023·2023-08-14

Q2 23EPS -22.58%·Rev n/aQ1 23EPS +26.32%·Rev n/aQ4 22EPS -100.00%*·Rev n/aQ3 22EPS +21.95%·Rev n/a⚠ consensus missing

Taysha Gene Therapies, Inc. TSHA

Hayleigh Collins — Director, Head of Corporate Communications

Sean Nolan — Chief Executive Officer

Sukumar Nagendran — President and Head of R&D

Kamran Alam — CHIEF FINANCIAL OFFICER

+188.2%1d on move date+187.7% vs SPY3d+161.2%5d+159.8%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more TSHA calls or request research access.

More TSHA calls Browse calls Request research access